<table>
<thead>
<tr>
<th>NAME</th>
<th>CTS AFFILIATION</th>
<th>DISCLOSURE</th>
<th>UPDATED</th>
</tr>
</thead>
</table>
| Darcy Marciniuk            | COPD Committee (Chair) and Canadian Respiratory Guidelines Committee (CRGC) and Canadian COPD Alliance | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).  
  - **Consultant Fee, Speaker’s Bureau, Advisory Committee:** AstraZeneca, Boehringer-Ingelheim, Canadian Agency for Drugs and Technologies in Health, GlaxoSmithKline, Health Canada, Health Quality Council of Saskatchewan, Novartis, Nycomed, Pfizer, Prince Albert Grand Council Chronic Disease Network, Public Health Agency of Canada, Saskatoon Health Region  
  - **Fiduciary Position** (other than CTS or CRHP): American College of Chest Physicians, Chest Foundation, Lung Association of Saskatchewan  
  - **Research/Program Grant Funding:** AstraZeneca, Boehringer-Ingelheim, Canadian Institutes of Health Research, GlaxoSmithKline, Lung Association of Saskatchewan, Novartis, Pfizer, Public Health Agency of Canada, Royal University Hospital Foundation, Saskatchewan Health Research Foundation, Saskatchewan Ministry of Health, Schering-Plough | March 14<sup>th</sup>, 2011 |
| Shawn Aaron                | COPD Committee (Executive)                                                      | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).  
  - **Advisory Board:** AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline  
  - **Consultant:** Health Canada Therapeutic Products Directorate, Ontario Ministry of Health and Long Term Care | May 13<sup>th</sup>, 2010 |
| Pat Bailey                 | COPD Committee                                                                  | Over the last two years, I have NOT had any affiliations (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest. | Jan 7<sup>th</sup>, 2011 |
| Meyer Balter               | COPD Committee (Executive) and Canadian Respiratory Guidelines Committee (CRGC) | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).  
  - **Advisory Board:** AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck, Novartis, Nycomed, Pfizer  
  - **Speaker:** AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Nycomed, Pfizer | May 4<sup>th</sup>, 2010 |
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
<th>Conflict of Interest Details</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donna Bleakney</td>
<td>External Reviewer</td>
<td>Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</td>
<td>May 12th, 2010</td>
</tr>
<tr>
<td>Dina Brooks</td>
<td>COPD Committee and Canadian COPD Alliance and CRC Planning Committee</td>
<td>Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest</td>
<td>April 29th, 2010</td>
</tr>
<tr>
<td>Scott Butcher</td>
<td>COPD Committee</td>
<td>Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</td>
<td>April 29th, 2010</td>
</tr>
<tr>
<td>Richard Debigare</td>
<td>COPD Committee</td>
<td>Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</td>
<td>April 29th, 2010</td>
</tr>
</tbody>
</table>
| Gail Dechman          | COPD Committee                                   | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).  
  - **Research/Program Grant Funding:** Dalhousie University, Lung Association of Nova Scotia, Nova Scotia Health Research Foundation, Social Sciences and Humanities Research Council  
  - **Membership** (other than CTS or CRHP): ATS, AACVPR, Canadian Physiotherapy Association, Nova Scotia College of Physiotherapy, Nova Scotia Physiotherapy Association | May 12th, 2010     |
| Gordon Ford           | COPD Committee (Executive)                        | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).  
  - **Advisory Board and Honoraria:** Abbott, Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer, Janssen-Ortho Inc.  
  - **Appointment:** Medical staff, Alberta Health Services  
  - **Research/Program Grant Funding:** Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer | July 21st, 2010     |
| Donna Goodridge       | COPD Committee                                   | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).  
  - **Appointment:** University of Saskatchewan, Associate Professor, College of Nursing  
  - **Speaker:** Lilly (sponsored her to attend educational session on depression in COPD for primary care physicians, Sept. 2009) | January 11th, 2011  |
<table>
<thead>
<tr>
<th>Name</th>
<th>Committee/Title</th>
<th>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest(s).</th>
<th>Date</th>
</tr>
</thead>
</table>
| Paul Hernandez       | COPD Committee (Executive) and Canadian Respiratory Guidelines Committee (CRGC) and Pulmonary Vascular Disease Committee and Canadian COPD Alliance | ▪ **Advisory Board and Consultant:** AstraZeneca, Actelion, Boehringer-Ingelheim, GlaxoSmithKline, Lilly, Merck Frosst, Novartis, Nycomed, Pfizer  
▪ **CME Development and Speaker:** AstraZeneca, Actelion, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer, Canadian Respiratory Conference, Atlantic Respirology and Critical Care Conference  
▪ **Medical Advisory Board:** Lung Association of Nova Scotia, Canadian COPD Alliance  
▪ **Research/Program Grant Funding:** AstraZeneca, Actelion, Boehringer-Ingelheim, CSL Behring, GlaxoSmithKline, Lilly, Novartis, Nycomed, Pfizer, Lung Association of Nova Scotia, Canadian Institute of Health Research, Capital Health Research Foundation  
▪ **Reviewer and Consultant:** Canadian Agency for Drugs and Technologies in Health | January 11th, 2011 |
| Vicki Kennedy        | COPD Committee                                                                  | Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.                                                                 | January 11th, 2011 |
| Julie Lauzon         | COPD Committee (A1AT)                                                           | **Appointment:** Clinical staff, University of Calgary                                                                                                                                           | Dec 7th, 2011      |
| Francois Maltais     | COPD Committee (Executive)                                                      | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest(s).  
▪ **Advisory Board:** Boehringer-Ingelheim, GlaxoSmithKline  
▪ **Research/Program Grant Funding:** Altana Pharma, Astra Zeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck Frosst, Novartis, Nycomed  
▪ **Research Chair in COPD:** Canadian Institutes of Health Research and GlaxoSmithKline  
▪ **Speaker:** Boehringer-Ingelheim, GlaxoSmithKline, Pfizer | January 11th, 2011 |
<table>
<thead>
<tr>
<th>Name</th>
<th>Committee</th>
<th>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</th>
</tr>
</thead>
</table>
| Denis O’Donnell   | COPD Committee     | **Advisory Board**: Boehringer-Ingelheim, Pfizer Canada  
**Consulting Fees and Speaker Bureau/Honoraria**: Boehringer-Ingelheim, GlaxoSmithKline, Pfizer Canada  
**Research/Program Grant Funding**: Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Pfizer. |
| Veronique Pepin   | COPD Committee     | **Advisory Board and Speaker**: GlaxoSmithKline  
**Research/Program Grant Funding**: GlaxoSmithKline, Canadian Institutes of Health Research, Canadian Lung Association, Fonds de la recherche en santé du Québec,  
**Reviewer**: Fonds de la recherche en santé du Québec |
| Darlene Reid      | COPD Committee     | Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest. |
| Graeme Rocker     | COPD Committee     | **Advisory Board**: Canadian Institutes of Health Research (Panel Scientific Officer)  
**Speaker**: GlaxoSmithKline, various Universities, Pfizer (Canada, USA, UK)  
**Research/Program Grant Funding**: Canadian Institutes of Health Research, Capital Health, CHEST foundation, Lung Association of Nova Scotia, GlaxoSmithKline, Medical Research Fund New Brunswick, Atlantic Health Sciences Corporation  
**Reviewer or Consultant**: CIHR, CMAJ, CHEST, Progress in Palliative Care, J Palliat Care, J Pain Sympt Manage, Annals Intern Med, Guest Editor, J Palliat Care 2011 and Progress in Palliative Care 2011 |

**Dates:**  
Denis O’Donnell: January 11th, 2011  
Veronique Pepin: May 2nd, 2010  
Darlene Reid: May 3rd, 2010  
Graeme Rocker: January 11th, 2011
<table>
<thead>
<tr>
<th>Name</th>
<th>Committee</th>
<th>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Sheel</td>
<td>COPD Committee</td>
<td>Over the last two years, I have not had any affiliation (financial or otherwise) with a commercial or other organization that could lead to a real or perceived conflict of interest.</td>
<td>May 4th, 2010</td>
</tr>
<tr>
<td>Michael Stickland</td>
<td>COPD Committee</td>
<td>Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s).</td>
<td>May 9th, 2010</td>
</tr>
</tbody>
</table>
|                  |                         | - **Appointment**: Co-director of the Centre for Lung Health, Covenant Health, Edmonton, Alberta  
|                  |                         | - **Research/Program Grant Funding**: GlaxoSmithKline, Heart and Stroke Foundation of Canada, Canadian Institutes for Health Research, Alberta Lung Association  
|                  |                         | - **Speaker**: GlaxoSmithKline  
| David Todd       | COPD Committee          | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). | April 29th, 2010   |
|                  |                         | - **Research/Program Grant Funding**: AstraZeneca, Ontario Thoracic Society  
| Shannon Walker   | COPD Committee and Membership | Over the last two years, I have had affiliations (financial or otherwise) with a commercial or other organization that could or has lead to a real or perceived conflict of interest (s). | April 28th, 2010   |
|                  |                         | - **Advisory Board**: AstraZeneca, GlaxoSmithKline, Nycomed  
|                  |                         | - **Appointments**: On-call services, Flame Oxygen, ICU Director, Cardiopulmonary Wellness Center at InterHealth (BC), UBC teacher for residents and medical students  
|                  |                         | - **Consultant**: Boehringer-Ingelheim  
|                  |                         | - **Speaker**: AstraZeneca, BC College of Family Physicians, BC College of Respiratory Therapists, Boehringer-Ingelheim, GlaxoSmithKline, Nycomed, Pfizer  